Article thumbnail

Drug and Cell Type-Specific Regulation of Genes with Different Classes of Estrogen Receptor β-Selective Agonists

By Sreenivasan Paruthiyil, Aleksandra Cvoro, Xiaoyue Zhao, Zhijin Wu, Yunxia Sui, Richard E. Staub, Scott Baggett, Candice B. Herber, Chandi Griffin, Mary Tagliaferri, Heather A. Harris, Isaac Cohen, Leonard F. Bjeldanes, Terence P. Speed, Fred Schaufele and Dale C. Leitman


Estrogens produce biological effects by interacting with two estrogen receptors, ERα and ERβ. Drugs that selectively target ERα or ERβ might be safer for conditions that have been traditionally treated with non-selective estrogens. Several synthetic and natural ERβ-selective compounds have been identified. One class of ERβ-selective agonists is represented by ERB-041 (WAY-202041) which binds to ERβ much greater than ERα. A second class of ERβ-selective agonists derived from plants include MF101, nyasol and liquiritigenin that bind similarly to both ERs, but only activate transcription with ERβ. Diarylpropionitrile represents a third class of ERβ-selective compounds because its selectivity is due to a combination of greater binding to ERβ and transcriptional activity. However, it is unclear if these three classes of ERβ-selective compounds produce similar biological activities. The goals of these studies were to determine the relative ERβ selectivity and pattern of gene expression of these three classes of ERβ-selective compounds compared to estradiol (E2), which is a non-selective ER agonist. U2OS cells stably transfected with ERα or ERβ were treated with E2 or the ERβ-selective compounds for 6 h. Microarray data demonstrated that ERB-041, MF101 and liquiritigenin were the most ERβ-selective agonists compared to estradiol, followed by nyasol and then diarylpropionitrile. FRET analysis showed that all compounds induced a similar conformation of ERβ, which is consistent with the finding that most genes regulated by the ERβ-selective compounds were similar to each other and E2. However, there were some classes of genes differentially regulated by the ERβ agonists and E2. Two ERβ-selective compounds, MF101 and liquiritigenin had cell type-specific effects as they regulated different genes in HeLa, Caco-2 and Ishikawa cell lines expressing ERβ. Our gene profiling studies demonstrate that while most of the genes were commonly regulated by ERβ-selective agonists and E2, there were some genes regulated that were distinct from each other and E2, suggesting that different ERβ-selective agonists might produce distinct biological and clinical effects

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). 17 Betaestradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-beta knockout (BERKO) mice.
  2. (2005). Chromosomewide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.
  3. (1998). Cluster analysis and display of genome-wide expression patterns.
  4. (2004). Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
  5. (2008). Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.
  6. (2008). Dimerization between aequorea fluorescent proteins does not affect interaction between tagged estrogen receptors in living cells.
  7. (2002). Disruption of estrogen receptor beta gene impairs spatial learning in female mice.
  8. (2003). Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis.
  9. (2003). Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial.
  10. (2001). ER beta inhibits proliferation and invasion of breast cancer cells.
  11. (2004). Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors {alpha} and {beta}.
  12. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial.
  13. (2003). Estrogen plus progestin and the risk of coronary heart disease.
  14. (2004). Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.
  15. (2004). Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.
  16. (2001). Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
  17. (2007). Estrogen receptor-beta: recent lessons from in vivo studies.
  18. (2007). Estrogen receptors: how do they signal and what are their targets.
  19. (2000). Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm
  20. (1994). Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.
  21. (2003). Evaluation of an estrogen receptor-beta agonist in animal models of human disease.
  22. (2002). for the Women’s Health Initiative
  23. (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.
  24. (1998). Generation and reproductive phenotypes of mice lacking estrogen receptor beta.
  25. (2006). Genome-wide analysis of estrogen receptor binding sites.
  26. (2004). GOstat: find statistically overrepresented Gene Ontologies within a group of genes.
  27. (2006). Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study.
  28. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial.
  29. (2002). Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium.
  30. (2005). Lack of functional estrogen receptor beta influences anxiety behavior and serotonin content in female mice.
  31. (2005). Lessons in estrogen biology from knockout and transgenic animals.
  32. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
  33. (2008). Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist.
  34. (2008). lumi: a pipeline for processing Illumina microarray.
  35. (2009). MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.
  36. (2002). Molecular determinants for the tissue specificity of SERMs.
  37. (2003). Multiple hypothesis testing in microarray experiments.
  38. (2007). Multiple Transcription Factor Elements Collaborate with Estrogen Receptor {alpha} to Activate an Inducible Estrogen Response Element in the NKG2E Gene.
  39. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
  40. (2006). Potential biological functions emerging from the different estrogen receptors.
  41. (2005). Reflections on the discovery and significance of estrogen receptor beta.
  42. (2007). Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract.
  43. (2008). Selective estrogen receptor- agonists repress transcription of proinflammatory genes.
  44. (2006). Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor.
  45. (2005). Stochastic models inspired by hybridization theory for short oligonucleotide arrays.
  46. (2004). Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.
  47. (2006). The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes.
  48. (2005). The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.
  49. (2006). The unexpected science of estrogen receptor-beta selective agonists: a new class of anti-inflammatory agents?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.